Next |
home / stock / apre / apre message board
Subject | By | Source | When |
---|---|---|---|
Dropping like a waterfall. | willlbone | investorshub | 11/11/2022 4:07:04 PM |
$APRE is climbing, it climbed today in spite | Nazirite | investorshub | 07/11/2022 8:22:41 PM |
Price target set for $3 buy and hold | Nazirite | investorshub | 07/11/2022 1:25:09 PM |
GM $APRE time to work | Nazirite | investorshub | 07/11/2022 12:51:35 PM |
High volume today 43x avg | Nazirite | investorshub | 07/08/2022 3:52:16 PM |
$APRE PT $3 can we see | Nazirite | investorshub | 07/08/2022 3:50:50 PM |
Hot Day for $APRE | Nazirite | investorshub | 07/08/2022 2:26:46 PM |
Aprea Therapeutics shares are trading higher after Wedbush | Nazirite | investorshub | 07/08/2022 2:21:47 PM |
Very strong! | subslover | investorshub | 07/08/2022 12:46:20 PM |
Why? Any insider good news? | stockforce | investorshub | 07/07/2022 12:48:19 AM |
Im joining in | MonopolyTrader | investorshub | 07/06/2022 11:11:08 PM |
coming off 53w low 1.46 just on thursday | TheFinalCD | investorshub | 02/28/2022 4:33:39 PM |
$APRE 8 Catalyst on the way not including | Jimmy Quick | investorshub | 10/14/2021 3:06:03 PM |
Aprea Therapeutics, Inc. (NASDAQ: $APRE): Phase 1/2 study | crudeoil24 | investorshub | 09/20/2021 11:45:49 AM |
On heavy watch for Monday. | dinogreeves | investorshub | 09/19/2021 4:38:56 AM |
If the Monday data can be very promising, | stockforce | investorshub | 09/17/2021 9:13:20 PM |
This could get some nice legs over 6+, | DailyX | investorshub | 09/17/2021 8:36:21 PM |
Good luck to all! Looks very promising! | stockforce | investorshub | 09/17/2021 8:10:26 PM |
Something special going on here with the gap | NATURES WAY | investorshub | 07/24/2021 6:39:02 PM |
CASH ON HAND $77 MILLION | Jimmy Quick | investorshub | 06/23/2021 2:23:41 PM |
News, Short Squeeze, Breakout and More Instantly...
Aprea Therapeutics Inc. Company Name:
APRE Stock Symbol:
NYSE Market:
Aprea Therapeutics Inc. Website:
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL...
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represent...
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been fo...